Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

BiondVax Pharmaceuticals Ltd. (BVXV)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
7.74-1.57 (-16.84%)
At close: 12:21PM EST
8.13 +0.39 (+5.04%)
After hours: 04:18PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close9.31
Open8.97
Bid7.71 x 800
Ask7.75 x 900
Day's Range7.61 - 9.29
52 Week Range5.34 - 34.90
Volume30,980
Avg. Volume8,250
Market Cap145.944M
Beta (5Y Monthly)2.36
PE Ratio (TTM)N/A
EPS (TTM)-2.30
Earnings DateMay 13, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for BVXV

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • BiondVax Pharmaceuticals Ltd.
    CARA: Lowering target price to $11.00CARA THERAPEUTICS INC has an Investment Rating of SELL; a target price of $11.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • PR Newswire

    BiondVax CEO to Present at the January 2023 Biotech Showcase in San Francisco

    BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced today that its CEO Amir Reichman will present at the January 9-11, 2023 Biotech Showcase conference. The Biotech Showcase Conference is taking place in San Francisco in parallel to the J.P. Morgan (JPM) 41st Annual HealthCare Conference.

  • GlobeNewswire

    BiondVax Congratulates Dirk Görlich on $1.4 million WLA Prize in Life Sciences

    JERUSALEM, Nov. 15, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) (“BiondVax”), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases, congratulates the company’s co-lead scientific research collaborator Professor Dr. Dirk Görlich, director at the Max Planck Institute for Multidisciplinary Sciences (MPI), on being

  • GlobeNewswire

    BiondVax Announces Plan to Implement ADS Ratio Change

    JERUSALEM, Nov. 10, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) (“BiondVax”), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases, announces today that it plans to effect a ratio change of the Company’s American Depositary Shares (ADSs) to its non-traded ordinary shares from the current ratio of one (1) ADS re

Advertisement
Advertisement